Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: J Pediatr. 2021 Sep 25;241:115–125.e2. doi: 10.1016/j.jpeds.2021.09.030

Table 3.

Correlates of Entering Weight Recovery Treatment and Changes in z-BMI, z-Weight, and z-Height After Starting Methylphenidate

Predictor Entered Weight Recovery Treatment (WRT) Δ z-BMI from 0 to 6 months Δ z-BMI from 0 months to end of follow-up Δ z-weight from 0 to 6 months Δ z-weight from 0 months to end of follow-up Δ z-height from 0 to 6 months Δ z-height from 0 months to end of follow-up
Correlation (SE) Sig. Correlation (SE) Sig. Correlation (SE) Sig. Correlation (SE) Sig. Correlation (SE) Sig. Correlation (SE) Sig. Correlation (SE) Sig.
Biometrics
Female +0.04 (0.08) −0.02 (0.09) −0.03 (0.09) −0.04 (0.09) −0.01 (0.09) +0.16 (0.08) +0.17 (0.09) *
Age in years at start of medication −0.13 (0.08) +0.09 (0.09) +0.20 (0.09) * +0.12 (0.09) +0.19 (0.09) * +0.30 (0.08) *** +0.16 (0.09)
Started medication after AUXAL-projected age of slowest growth −0.09 (0.08) +0.04 (0.09) +0.12 (0.09) +0.08 (0.09) +0.18 (0.08) * +0.28 (0.08) ** +0.14 (0.09)
Height (z) at start of medication −0.20 (0.08) * +0.19 (0.08) * +0.14 (0.09) +0.24 (0.08) ** +0.10 (0.09) −0.07 (0.09) −0.13 (0.09)
Weight (z) at start of medication −0.44 (0.07) *** +0.28 (0.08) ** +0.07 (0.09) +0.28 (0.08) *** +0.05 (0.09) +0.08 (0.09) +0.00 (0.09)
BMI (z) at start of medication −0.45 (0.07) *** +0.20 (0.08) * −0.01 (0.09) +0.16 (0.08) −0.01 (0.09) +0.15 (0.09) +0.05 (0.09)
Midparental height in centimeters (measured or reported) −0.09 (0.09) +0.06 (0.09) +0.10 (0.09) +0.11 (0.09) +0.11 (0.09) −0.10 (0.09) −0.07 (0.09)
Biometric deltas
Change in weight (z) from start of medication to +6 months - - - - - +0.14 (0.09) +0.20 (0.09) *
Change in weight (z) from start of medication to last available visit - - - - - - +0.42 (0.07) ***
Symptoms
Parent rating of hyperactivity/impulsivity symptoms of ADHD at study entry −0.08 (0.09) −0.05 (0.09) −0.06 (0.09) −0.04 (0.09) −0.05 (0.09) −0.01 (0.09) −0.08 (0.09)
Parent rating of inattention symptoms of ADHD at study entry +0.06 (0.09) +0.06 (0.09) −0.09 (0.09) +0.08 (0.09) −0.07 (0.09) +0.02 (0.09) +0.02 (0.09)
Parent rating of ODD symptoms at study entry −0.15 (0.08) +0.03 (0.09) −0.09 (0.09) +0.03 (0.09) −0.12 (0.09) −0.07 (0.09) −0.12 (0.09)
Medication
Parent rating of loss of appetite at optimization was moderate/severe +0.10 (0.09) −0.14 (0.09) −0.14 (0.09) −0.20 (0.09) * −0.19 (0.09) * −0.28 (0.08) ** −0.16 (0.09)
Percent of days medicated in first 6 months after starting medication +0.37 (0.07) *** −0.36 (0.07) *** - −0.38 (0.07) *** - −0.12 (0.09) -
Percent of days medicated from start of medication to last available visit +0.32 (0.08) *** - −0.38 (0.08) *** - −0.40 (0.07) *** - −0.26 (0.08) **
Total MPH intake (kg) in first 6 months after starting medication +0.33 (0.07) *** −0.36 (0.08) *** - −0.34 (0.08) *** - +0.05 (0.09) -
Total MPH intake (kg) from start of medication to last available visit +0.28 (0.08) *** - −0.23 (0.09) * - −0.30 (0.09) *** - −0.32 (0.08) ***

Note. SE = standard error, AUXAL = structural auxologic analysis model, BMI = body mass index, ADHD = Attention-Deficit/Hyperactivity Disorder, ODD = Oppositional Defiant Disorder, MPH = methylphenidate, kg = kilograms.

Correlations are Pearson correlations. “Sig.” indicates statistical significance of correlation. All models were estimated using full-information maximum likelihood and included the 141 children who ever took medication. Auxiliary variables were female, age in years at study entry, entered study after AUXAL-projected age of slowest growth, z-height at study entry, z-weight at study entry, and z-BMI at study entry.

*

p < .05,

**

p < .01,

***

p < .001